[Skip to Content]
[Skip to Content Landing]
September 1975

Pilocarpine OcusertsLong-Term Clinical Trials and Selected Pharmacodynamics

Author Affiliations

From the Glaucoma Clinic, the Wilmer Institute, the Johns Hopkins Hospital, Baltimore.

Arch Ophthalmol. 1975;93(9):771-775. doi:10.1001/archopht.1975.01010020665001

For up to one year, 22 patients with ocular hypertension or glaucoma wore a seven-day sustained release device (Ocusert) containing pilocarpine with acceptable retention and no important side-effects. Comparison of prestudy medical regimens using eye drops with those defined as minimum controlling concentrations indicated a high rate of overmedication. The hypotensive effect of two Ocusert strengths was compared to four pilocarpine drop concentrations. Concurrent administration of epinephrine drops did not interfere with Ocusert action and had the anticipated additive effect. Further study indicated the need for continuous wearing and delimited the effective duration of action for single Ocuserts to seven days.

Podos SM, Becker B, Asseff C, et al:  Pilocarpine therapy with soft contact lenses . Am J Ophthalmol 73:336-341, 1972.
Asseff CF, Weisman RL, Podos SM, et al:  Ocular penetration of pilocarpine in primates . Am J Ophthalmol 75:212-215, 1973.
Armaly MF, Rao KR:  The effect of pilocarpine Ocusert with different release rates on ocular pressure . Invest Ophthalmol 12:491-496, 1973.
Worthen DM, Zimmerman TJ, Wind CA:  An evaluation of the pilocarpine Ocusert . Invest Ophthalmol 13:296-299, 1974.
Macoul K, Pavan-Langston D: Pilocarpine Ocusert therapy for sustained glaucoma therapy. Read before the Association for Research in Vision and Ophthalmology, Sarasota, 1974.
Lee PF, Shen YT: Clinical evaluation of the pilocarpine Ocusert in the management of glaucoma. Read before the Association for Research in Vision and Ophthalmology, Sarasota, 1974.